H-1129

H-1129 is a Rho kinase inhibitor optimized from a seed compound in our in-house compound library, which mainly consists of protein kinase inhibitors. We had developed it with indications for glaucoma and ocular hypertension until 2019; however, development was discontinued following a domestic Phase III clinical trial. Subsequently, from the standpoint of maximizing the value of this asset, we examined the possibility of applying it to other diseases (repositioning), and in 2025, decided to develop it as a therapeutic agent for keratoconjunctival diseases based on immune disorders.

Keratoconjunctival diseases are a general term for conditions that cause inflammation and damage to the cornea and conjunctiva, leading to symptoms such as dryness of the eye, redness, pain, and blurred vision. When severe, these conditions can potentially exert a serious impact on visual function. The causes of immune abnormalities include chronic disorders resulting from autoimmune or allogeneic immune responses, as well as excessive immune-inflammatory responses, and standard treatments mainly consist of immunosuppression or symptomatic therapy.

Against this background, we consider that keratoconjunctival diseases based on immune disorders markedly reduce patients’ QOL and that there is a high medical need.

Keratoconjunctival diseases based on immune disorders	●※ Japan

*Currently preparing for clinical trials. Plan to consult with the authorities at the start of Phase II

Development Progress